PhI­II bust forces Ul­tragenyx to scrap drug for rare mus­cle dis­ease

An­a­lysts had been spec­u­lat­ing that a suc­cess in Ul­tragenyx’s Phase III study of Ace-ER for rare cas­es of GNE my­opa­thy could trig­ger some near-term reg­u­la­to­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER